Cell Source (PK)【CLCS】銘柄情報

Cell Source Inc (PK) (CLCS) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.93

( -3.13% )

買値

0.6426

売値

0.945

出来高

8,850

0.77 日の範囲 0.95

0.27 52 週間の範囲 2.25

時価総額

63.19M

前日終値

0.96

始値

0.8995

時刻

150

0.93

最終取引時間

00:55:58

財務取引量

US$ 8,029

VWAP

0.907204

平均取引量 (3 か月)

US$ 3,116

発行済株式数

67,945,856

配当利回り

PER

-5.76

1 株当たり利益 (EPS)

-0.14

歳入

純利益

-4.72M

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune respo... Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

cell-source.com

本社

New York, United States

設立

2026

Cell Source Inc (PK) is listed in the Healthcare sector of the その他OTC with ticker CLCS. The last closing price for Cell Source (PK) was US$0.96. Over the last year, Cell Source (PK) shares have traded in a share price range of US$ 0.27 to US$ 2.25.

Cell Source (PK) currently has 67,945,856 shares in issue. The market capitalisation of Cell Source (PK) is US$63.19 million. Cell Source (PK) has a price to earnings ratio (PE ratio) of -5.76.

Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week

Plans to expand clinical program and uplist to the NASDAQ were also presented. NEW YORK, NY / ACCESS Newswire / May 21, 2026 / Cell Source, Inc...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.2875	44.7470817121	0.6425	0.96	0.6425	5516	0.91375818	CS
4	0.16	20.7792207792	0.77	0.96	0.6425	3706	0.82262506	CS
12	0.1602	20.8106001559	0.7698	0.975	0.555	3489	0.82526197	CS
26	0.33	55	0.6	2.25	0.41335	5043	0.8306526	CS
52	0.64	220.689655172	0.29	2.25	0.27	6115	0.56417395	CS
156	0.9289	84445.4545455	0.0011	2.25	0.0002	12693	0.43223068	CS
260	-0.92	-49.7297297297	1.85	2.25	0.0002	10626	0.52647127	CS